Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Immunogen Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Eli Lilly, Livent, Super Micro Computer And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
May 03, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 01, 2023
Via
Benzinga
Crude Oil Rises 2.5%; Chevron Tops Q1 Expectations
April 28, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 200 points on Friday. The Dow traded up 0.60% to 34,029.17 while the NASDAQ rose 0.40% to 12,190.35. The S&P 500,...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 28, 2023
Via
Benzinga
Why Shares of ImmunoGen Jumped Friday
April 28, 2023
The biotech company's first-quarter report had plenty of good news.
Via
The Motley Fool
Immunogen's Earnings: A Preview
April 27, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Analyst Ratings for Immunogen
January 23, 2023
Via
Benzinga
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 28, 2023
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% on Thursday.
Via
Benzinga
Intel, Saia, Charter Communications And Other Big Stocks Moving Higher On Friday
April 28, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Analyst Ratings for Immunogen
December 30, 2022
Via
Benzinga
6 Analysts Have This to Say About Immunogen
December 30, 2022
Via
Benzinga
What 6 Analyst Ratings Have To Say About Immunogen
December 30, 2022
Via
Benzinga
ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug
April 28, 2023
ImmunoGen Inc (NASDAQ: IMGN) shares are surging Friday morning following its impressive first-quarter performance.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 28, 2023
Via
Benzinga
Earnings Scheduled For April 28, 2023
April 28, 2023
Companies Reporting Before The Bell • GrafTech International (NYSE:EAF) is likely to report quarterly loss at $0.01 per share on revenue of $123.00 million.
Via
Benzinga
Looking Into Immunogen's Return On Capital Employed
November 28, 2022
Via
Benzinga
After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst
November 16, 2022
Via
Benzinga
Could This Move Make Vertex's Next Blockbuster Even Bigger?
April 12, 2023
Vertex is showing it can branch out beyond its cystic fibrosis specialty.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 07, 2023
Via
Benzinga
Why Shares of MacroGenics Jumped Thursday
March 09, 2023
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.
Via
The Motley Fool
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
March 01, 2023
Via
Benzinga
What You Missed On Wall Street On Friday
December 31, 2022
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.
Via
Talk Markets
Expert Ratings for Immunogen
November 16, 2022
Via
Benzinga
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
December 30, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
December 30, 2022
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.
Via
Benzinga
ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
December 28, 2022
The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a...
Via
Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...
Via
Talk Markets
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Via
Benzinga
Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around
November 23, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though."
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.